# Teva Pharmaceutical Industries Limited (TEVA) — Stock CV

Teva Pharmaceutical Industries Limited is a $48.1B healthcare company. Revenue grew 4.1% over the last year, it keeps 4¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 63.2× earnings — near the highest of its own history.

> Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US.

## Identity

- **Ticker**: TEVA
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: TEL AVIV
- **Employees**: 32 842
- **Website**: https://www.tevapharm.com
- **Market cap**: $48.1B
- **Last price**: $41.21
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $17.3B
- **Net income**: $706M
- **Free cash flow**: $1.35B
- **Net cash**: $1.74B
- **P/E**: 63.2
- **Revenue growth (YoY)**: 4.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 37 |
| Growth | 56 |
| Profitability | 50 |
| Health | 44 |
| Quality | 53 |
| Moat | 58 |

## Qualifications (beginner checklist) — 7 of 10 passed

- [x] Revenue growing — +4.1% YoY
- [x] Profitable — $706M TTM
- [x] Profit growing — +186.0% YoY
- [x] Generates cash — $1.35B TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $48.1B market cap
- [x] Not printing shares — +6.2% shares over ~5y
- [ ] Proven track record — 2/9 profitable years
- [ ] Financially stable — Altman Z 0.6 — distress
- [ ] Valuation not extreme — P/E 63.2

## Experience (career milestones)

- **FY2025** — Best year on record: $1.41B net income
- **FY2021** — Turned profitable: $417M net income after a loss year
- **FY2021** — Became debt-free: cash now exceeds total debt
- **FY2017** — Revenue already above $10B: $22.4B in first reported year
- **FY2017** — Positive free cash flow every year since: 9-year streak
- **2015** — Teva acquired Auspex Pharmaceuticals for $3.5 billion growing its CNS portfolio
- **2011** — Teva bought Cephalon for US$6.8 billion
- **Dec 23, 2008** — Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought…
- **2006** — Teva acquired its U.S. rival Ivax Corporation for $7.4 billion
- **2003** — Teva announced its intentions to acquire Sicor Inc. for $3.4 billion
- **1995** — Teva acquired Biogal Gyógyszergyár Rt. (Debrecen, Hungary) and acquired ICI (Italy)
- **1980** — Teva acquired Ikapharm, then Israel's second largest drug manufacturer
- **1964** — Assia and Zori merged and in 1968 acquired a controlling stake in Teva
- **1951** — Feuchtwanger initiated an initial public offering to raise capital through the newly founded Tel-Aviv Stock…
- **1901** — Teva's earliest predecessor was SLE, Ltd., a wholesale drug business founded in 1901 in Ottoman Empire's…

## Strengths

- High gross margin (52.9%)
- Net cash position after subtracting debt from cash
- High returns on invested capital (ROIC 22.8%)
- Piotroski F-Score 7/9 — fundamentally strong checklist

## Watch-outs

- Altman Z-Score 0.63 — elevated financial-distress risk
- Net debt would take ~9.8 years of free cash flow to repay
- Loss-making in 7 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $15.9B | $417M | $236M |
| FY2022 | $14.9B | -$2.35B | $1.04B |
| FY2023 | $15.8B | -$559M | $842M |
| FY2024 | $16.5B | -$1.64B | $749M |
| FY2025 | $17.3B | $1.41B | $1.15B |

---

Source: https://stockcv.com/TEVA — derived from company filings; may be delayed or incomplete. Information, not investment advice.